OUR
HISTORY

OUR HISTORY

Introducing the footsteps of inno.N in creating a healthy world and a story of innovation.

2 0 2 0

2020

A New Beginning for our 100- year journey

Our pioneering ideas create a new future for the pharmaceutical industry.

  • change the corporation name to InnoN.
    04.2020
    • Changed our company name to inno.N, marking a new beginning of our journey to become a leading global pharmaceutical industry.
  • Launch of the K-CAB
    02.2020
    • Launched the K-CAB.
      Achieved revenue of 35.9 billion won within just 11 months.

    P-CAB
    MEGA HIT

    300억

2 0 1 9

2019

A New Beginning

We found our way to more creations.

  • Certification of the Global Anti-Corruption Management System ‘ISO 37001’
    11.2019
    • Received ‘ISO 37001’Certification of Global
    • Anti-Corruption Management System Established the industry’s largest corporate compliance policies.

    Certification
    ISO 37001

  • Launch of Condition pills Renewals
    11.2019
    • Launched tablet-form CONDITION

    CONDITION
    INNOVATION

  • K-CAB LAUNCHING SYMPOSIUM
    03.2019
    • Launched Korea's 30th new drug K-CAB.

    P-CAB
    NEW HIT

2 0 1 8

2018

A New Beginning

We found our way to more creations.

  • 'K-CAB‘Tab.(ingredient name: Tegoprazan), in-house developed new drug for gastroesophageal reflux disease, has received a license from the Ministry of Food and Drug Safety
    07.2018
    • ‘K-CAB‘Tab. (Ingredient name: Tegoprazan), Successfully in-house developed a new drug for gastroesophageal reflux disease, licensed by the Ministry of Food and Drug Safety
    • Korea’s No.30 New Drug

    A NEW BEGINNING
    OF P-CAB

  • Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to NCPC GeneTech in China
    01.2018
    • Out-licensed the second-generation EPO 'CJ-40001'
      (a renal anemia treatment) technology to NCPC GeneTech in China

    BUILDING
    THE NEW
    COMPANY

  • 01.2018
    • Achieved 'AA' rating for the Corporate Compliance Program
    'Achieved 'AA' rating for the Corporate Compliance Program
2 0 1 7

2017

A great leap towards the global market

inno.N aspires to reach beyond Korea to the global market

  • Out-licensed the second-generation EPO 'CJ-40001' (a renal anemia treatment) technology to NCPC GeneTech in China
    09.2017
    • Out-licensed the second-generation EPO 'CJ-40001
      (a renal anemia treatment) technology to YL Biologics in Japan
  • 05.2017

    Opened inno.N’s representative office in Vietnam (as of May 1)

  • 창사 3주년 기념식 사진
    04.2017
    • The foundation’s third-year anniversary
    • The 2nd Self-Compliance Day
    The 2nd Self-Compliance Day
  • 03.2017
    • Signed a MOU for 2017 Volunteer Work with Seoul Volunteer Center
    Signed a MOU for 2017 Volunteer Work with Seoul Volunteer Center
2 0 1 6

2016

Secure the future’s innovative technology
through Open Innovation.

12.2016 Reached KRW 500 billion in sales
  • inno.N, Kang Seok-hi Representative Director Election of Autonomy Compliance Manager
    12.2016
    • SeokHee KANG (CEO of inno.N) was appointed as Self Compliance Manager
    • Reached KRW 500 billion in sales

    500,000 MILLION

  • R&D open innovation forum for venture invitations in the US and Europe held
    09.2016
    • Hosted the R&D Open Innovation Forum, attended by multiple business ventures from the U.S and Europe
    • Launched Korea’s first fixed-dose combination IMD for hypertension, ‘MACHKHAN'
    Domestic first release of Mach-Khan, hypertension combined improvement drug
  • Held the launch event of the fixed-dose combination IMD for hypertension, ‘MACHKHAN’
    08.2016
    • Launched LUKIO
    • Held the launch event of the fixed-dose combination IMD for hypertension, ‘MACHKHAN’
    • Signed a MOU with Seoul Voluntary Center for Employees & Executives Voluntary Work
    Mach clamping tablet
  • Launched the new version of HUTGAESOO
    07.2016

    Launched the new version of HUTGAESOO

    HUTGAESOO products
  • Hosted the R&D Open Innovation Forum with many business ventures from the U.S and Japan
    04.2016

    Hosted the R&D Open Innovation Forum with many business ventures from the U.S and Japan

  • The foundation’s second-year anniversary of foundation
    04.2016
    • The foundation’s second-year anniversary of foundation
    • Established Self Compliance Day (4.1)
    Establish day of autonomous compliance (April 1)

    2nd
    ANNIVERSARY

  • Ra mắt quảng cáo TV về 'CONDITION' tại Việt Nam
    03.2016

    Released the first TV Advertisement for ‘CONDITION’ in Vietnam

    Condition of Vietnamese products
2 0 1 0

2010

inno.N’s new journey into the world

Exporting more products to the global markets, inno.N consistently moved forward with groundbreaking innovations that contributed to a healthier world.

  • Developed a new treatment for GERD ˝CJ-12420(Tegoprazan)˝, Transferred such a technology to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd
    2015

    Developed a new treatment for GERD ˝CJ-12420(Tegoprazan)˝, Transferred such a technology to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd

    EXPORT
    cj-12420

  • inno.N launch
    2014
    • Launched ‘VOGMET’, a fixed-dose combination IMD for diabetes
    • Established inno.N Corporation
    • Debuted CONDITION in 3 different countries (China, Vietnam, and Japan)
    Debuted CONDITION in 3 different countries (China, Vietnam, and Japan)
  • inno.N Erroneous Factory
    2012
    • Won the Beautiful Architecture Award for Cheongwon-gun Office for Osong Plant
    • `HUTGAESOO` became the No.1 dulcis drink in market share (2012. Nielsen Research)
    • Upgraded `CONDITION` to `HUTGAE CONDITION` in celebration of its 20th anniversary
2011 Reached KRW 400 billion in sales
  • Anti-hangover drink CONDITION was designated as the global leading product by the Ministry of Knowledge & Economy
    2011
    • Launched ‘MOSAONE’, ‘ABELTAN’, and ‘LUKAIR’
    • Anti-hangover drink `CONDITION` was designated as the `global leading product` by the Ministry of Knowledge & Economy'
    • Launched `CLOSONE`, a fixed-dose combination for antithrombotic therapy
    • Formed a joint R&D partnership with Bioleaders to develop anti-cancer drugs and vaccines
    Release of anti-thrombotic agent 'Closone'
  • Completed the construction of manufacturing buildings for oral APIs at Daeso Plant
    2010
    • Completed the construction of manufacturing buildings for oral APIs at Daeso Plant
    • Completed the construction of Osong Plant under international standards
    • Launched `HEPCURE`
    • Launched `CONDITION HUTGAESOO (Hovenia Dulcis)`, a beverage.
    health drink 'HUTGAESOO'
2 0 0 0

2000

Lead the market with R&D

inno.N became recognized as the trailblazer in Korea’s pharmaceutical industry by means of investment in continuous R&D.

  • Strategic partnership for injectable solution business (Medi Pharma Plan)
    2009
    • Strategic partnership for injectable solution business (Medi Pharma Plan)
    • Signed a MOU with the Traditional Medicine Center of Chungbuk Technopark to develop therapeutic ingredients and new drugs
    • Successfully penetrated the CNS market
    • Formed a co-promotion/marketing alliance on `SINGULAIR` with MSD Korea and launched `LUKAIR`
    • Launched `HUTGAE CONDITION POWER`
    HUTGAE CONDITION POWER Products
  • Misdirective global level misdirected factory construction within the biotechnology complex
    inno.N Only Gomatsu Biotechnology
    2008
    • Signed a joint-investment agreement with `Neuralstem` (a U.S. based stem-cell company)
    • Commenced the construction of a globally competitive plant in Osong Bio-Health Science Technopolis (with an investment worth KRW 150 billion)
  • 2007

    Reached revenue of KRW 300 billion

2007 inno.N
Reached revenue of KRW 300 billion
  • Acquisition of Japanese and Korean medicines, merger
    2006

    Acquired Hanil Pharmaceutical

    300,000 MILLION

  • NEW
    PRODUCTS

    Sinbuster (Symbatstatin First Generic) for treatment of hyperlipidemia released
    Pseudomonas aeruginosa vaccine 'Da stab' Domestic new drug No. 7
    2003
    • Registered `PSEUDOVACCIN`, a pseudomonas aeruginosa vaccine & Korea`s No.7 new drug
    • Launched an anti-hyperlipidemic medication `SIMVASTA`(the first generic drug of simvastatin)
  • 2002
    • Established a hepatitis B vaccine plant and began exporting to Myanmar
    • Launched `CEFMENOXIME`, a cephalosporin antibiotic (sterile product)
  • CJ CheilJedang Pharma New Jersey office founded
    2001
    • Advanced R&D and overseas business activities by establishing CJ CheilJedang Pharma New Jersey office
    • Launched `CEFOTIAM`, a cephalosporin antibiotic
    • Developed a fluid (I.V. solution) stabilization technology and developed multiple applications into current products
  • OBU (Oncology Business Unit) launched
    2000

    Established OBU (Oncology Business Unit) and launched the new antiemetic `CAMPTO`, officially expanding the company’s reach to the anticancer medicine marketư

    Infusion products

    CANCER UNIT

1 9 9 0

1990

Open new chapters

inno.N opened its new chapters in business by successfully localizing many drugs while unlocking USD 100 million in exports, the first in the domestic industry to do so.

  • R&D laboratory at capital letters factory
    1999
    • Awarded the Chang Young-sil Award for `EPOKINE
    • Received BGMP (Bulk Good Manufacturing Practices) for Daeso Plant
    EPOKINE products
  • Release of Epoca with anemia agent
    1998
    • Launched a new anemia treatment, `EPOKINE` (first to be independently developed in Korea & third in the world)
    • Reached 1 hundred million dollars in exported revenue, the first in Korea’s pharmaceutical industry to do so and launched a Cepha antibiotic ‘CEFTAZIDIME’.
    Three breaking antibiotic 'Chef Riding Dim' released
  • Release of 'Basin' for treatment of diabetes
    1997
    • Co-developed a diagnostic reagent for epidemic hemorrhagic fever using genetic engineering technology with the National Institutes of Health (first in the world)
    • Developed chicken pox vaccine - Launched `LEGIOFREE` (legionella remover)
    • Received ‘New Technology’ label (KT Label) for `LEGIOFREE`
    • Won the Prime Minister Award at the Excellent Patent Product Contest for Pseudomonas Aeruginosa vaccine
    • Launched antidiabetic `BASEN`
  • 1995
    • `CITOPCIN` injectable received “New Technology” label (KT Label) and won Chang Young-sil Award
    • Developed the world’s first Pseudomonas Aeruginosa vaccine
  • Hepatitis B vaccine 'Hepaccin B' WHO certification
    1993
    • Launched the cephalosporin antibiotic `CEFTRIAXONE`
    • Injectable fluids was certified as KGMP (Korea Good Manufacturing Practice)
    • Hepatitis B vaccine `HEPACCINE-B` was certified by WHO and delivered overseas for use by UN
    HEPACCINE-B product

    inno.N
    GLOBAL

1992 Reached KRW 100 billion in sales
  • Hangover release drink 'Condition' released
    1992
    • Completed the construction of the production facility for injectable fluids
    • Launched `KINDORASE`, `CEFOTAXIME`, `VANCOMYCIN`, and `CEFAZOLIN`
    • KINDORASE (antiphlogistic enzyme) won Chang Young-sil Award
    • Released an anti-hangover drink `CONDITION`
    Infusion agent factory completed
  • 1991

    Initiated the production of `7-ACA`, API for Cepha antibiotics

  • Completion of production of drug substance production plant
    1990

    Completed the construction of the manufacturing plant (Daeso Plant) for APIs

    FACTORY
    daeso

1 9 8 0

1980

The beginning of our journey to create a healthier world

inno.N started as Pharmaceutical BU of CJ CheilJedang Corp. in 1984.

  • 1989

    Launched API for Cepha antibiotics `7-ACA`, anti-virus `Alpha- Interferon`, and antimicrobial `CIPROFLOXACIN`

  • Release of hepatitis vaccine 'Hepaccin B'
    1986
    • Completed the construction of Icheon Plant
    • Launched the hepatitis vaccine `HEPACCINE-B` using only domestically developed technologies
    Ikawa factory completed
  • Participation in Pharmaceutical Business, Establishment of Research Institute
    1984
    • Acquired Yupung Pharmaceuticals
    • Started our business in pharmaceuticals and established a research institute
    • Established a U.S.-based R&D center (ETI)
    • Developed interferon for human lymphocytic cells